Nebraska Faces Losses to Drug Development, Jobs and Patient Health According to New Study

A new study estimates that proposed Federal Government-mandated drug pricing policies will amount to 237 fewer FDA approvals and up to 4,000 lost jobs for Nebraska workers over the next 10 years.

Announcement from We Work For Health and Vital Transformation

A new study estimates that there would be 237 fewer FDA approvals of new medicines for patients battling cancer, neurological, and rare and infectious diseases over the next decade as well as over 4,000 lost jobs for Nebraska workers if proposals to expand federal government-mandated drug pricing policies are implemented. Among the proposals under consideration is allowing Medicare to set prices for specific drugs five years after FDA approval, which would lead to significant lost therapies, innovation, and jobs in the biopharma ecosystem at an even more accelerated pace. These proposals are included in the White House’s FY 2024 budget as well as the Senate’s SMART Prices Act.

Research firm Vital Transformation modeled the impacts of expanded federal government-mandated drug pricing policies at five years following FDA approval. The study analyzed the reduction of new drug approvals and loss of jobs if these policies or others similar to them were enacted into law.

“We have been working to grow Nebraska’s bioscience sector since 2005 and it is deeply disheartening to see the numbers in this new report from Vital Transformation,” said Rob Owen, Executive Director of Bio Nebraska. “Misguided policies such as government price controls on medicines will significantly impact not only the well-being of patients, but our state’s economic diversity. Our elected leaders should seriously reconsider any future proposals that call for government price controls.”

“At a time when the biopharmaceutical industry is just beginning to experience the negative impacts of the Inflation Reduction Act’s government-mandated drug pricing policy, any new proposal only adds fuel to the fire and reinforces a deeply misguided and flawed approach,” said Tom Kowalski, national co-chair of We Work For Health. “This latest study demonstrates just how bad the damage could be should these plans be implemented.”

Key Study Highlights:

The study found that, if proposed expansions of government-mandated drug pricing policies are implemented, there are serious consequences around the development of and investment in new medicines, and significant job losses in major innovation hubs like Nebraska.

  • Lost Therapies: More than 80 currently available therapies of 121 identified for price setting – approximately 70% – would likely not have been developed had the pricing provisions been in place prior to their development.
  • Lost Innovation: There would be 237 fewer FDA approvals of new medicines or new uses over a 10-year period. Impacts of the proposed policies will be felt most heavily in many areas of unmet need, particularly in oncology, neurology, and rare and infectious diseases.
  • Lost Jobs & Investment: This would result in a loss of between 560 to 860 direct biopharmaceutical industry jobs and a total loss of as many as 4,000 jobs in Nebraska. There would also be a loss of ecosystem investments into 50 different therapeutic indications, with significant impacts in areas of unmet need including oncology, neurology, and rare conditions.
  • Specifically, We Work For Health is hopeful that Congress will preserve incentives for small molecule research. Under the IRA, biologics have a 13-year period before the government can intervene and mandate drug prices, but small molecule drugs are limited to nine years prior to negotiation. This discrepancy will lead to a reduction in investment in small molecule drugs.

At a time when the biosciences industry has illustrated its value through not only medical advancements, but in strong employment opportunities it is critical that Nebraska’s Congressional delegation consider the existing unintended consequences of the IRA. Enacting additional government price controls such as the Senate’s SMART Pricing Act before the current law’s consequences are fully understood would be a mistake.

Earlier this month, Vital Transformation and the Biotechnology Innovation Organization (BIO) issued a separate study showing that patients could lose access to at least 40% of new medicines that wouldn’t be developed as a result of government-mandated drug pricing policies contained in the Inflation Reduction Act. This equates to as many as 139 therapies not being developed over the next 10 years.

The new study by We Work For Health and Vital Transformation modeled the impacts on industry revenues, jobs and future research and development investments. The analysis was performed by Vital Transformation’s consulting economist Dr. Harry Bowen, research partner Dr. Daniel Gassull and CEO Duane Schulthess. For the full study, please visit Vital Transformation or We Work For Health.

About We Work For Health

Since 2007, We Work For Health (WWFH) has been bringing together national and local business leaders, labor, biopharma, patient advocacy and other healthcare-related stakeholders. WWFH is dedicated to promoting policies and initiatives that not only foster innovation and facilitate the delivery of lifesaving or life-enhancing medicines, but also value both the workforce and significant contributions of the biopharmaceutical sector to economies at the national, state and local levels.

About Vital Transformation

Vital Transformation understands the implications of new medical procedures, technologies, and policies. We measure their impact on current clinical practices in close collaboration with health care professionals, researchers, and regulators. Through our web platform, client network, and Vital Health Podcast series, we are able to communicate our findings with international decision makers and stakeholders.